AUTHORS
Michael R. Grunwald, MD, Jeffrey Zwicker, MD2, Valkal Bhatt, PharmD3, Jennifer E Hamer-Maansson, MS4, Britnie Thomas, PhD5, Stephen Oh, MD, PhD6
AFFILIATIONS
1 Atrium Health Levine Cancer Institute and Wake Forest University School of Medicine, Charlotte, North Carolina, United States
2 Memorial Sloan Kettering Cancer Center, New York, New York, United States, Weill Cornell Medical College, New York, New York, United States
3 Incyte Corporation, Wilmington, Delaware, United States
4 Incyte Corporation, Wilmington, Delaware, United States
5 Incyte Corporation, Wilmington, Delaware, United States
6 Washington University School of Medicine, St. Louis, Missouri, United States
ABSTRACT
Introduction: In patients with polycythemia vera (PV), disease progression can lead to transformation to myelofibrosis (MF), a major cause of morbidity and mortality. We previously identified multiple predictors of PV transformation to MF (Grunwald MR, ASH 2023); however, data remain limited on risk factors associated with earlier stages of PV progression. Here, we analyze patients with clinically accelerating or progressive PV using data from the Prospective Observational Study of Patients with Polycythemia Vera in US Clinical Practices (REVEAL) to identify risk factors associated with disease progression without transformation.
Methods: REVEAL enrolled adults with a physician-reported PV diagnosis across 227 US clinical sites. Patients identified as having transformed disease to MF were excluded from this analysis. Progressive PV was defined as a change to new therapy that occurred after at least 1 of the following clinical features of worsening disease: increased symptom burden (≥20% increase in total symptom score), uncontrolled hematocrit (>45%), or new/worsening splenomegaly. The control group comprised patients who did not meet the definition of progressive PV and who enrolled either without treatment (watchful waiting) or with phlebotomy only. Univariate and multivariate logistic regression analyses were used to identify risk factors associated with progressive PV.
Results: REVEAL enrolled 2510 patients, of whom 2023 had a confirmed PV diagnosis. Of patients with confirmed PV, 244 (12.1%) had progressive PV and 457 (22.6%) met the criteria for nonprogressive controls. Patients with progressive PV were older than the control group (median age 66.0 years vs 63.0 years, P=0.0014), with 169 (69.3%) and 277 (60.6%) patients aged ≥60 years in each group, respectively (P=0.0234). Median (range) time from PV diagnosis to enrollment (disease duration) was similar between groups (2.6 [0.0, 38.5] years vs 2.9 [0, 30.3] years). Median baseline levels of hematocrit (0.47 L/L vs 0.46 L/L, P=0.0019), white blood cells (WBCs) (11.5×109/L vs 9.7×109/L, P<0.0001), and platelets (461.0×109/L vs 347.0×109/L, P<0.0001) at enrollment were significantly higher in the progressive PV group compared with the control group. Nonsignificant differences in race, sex, and history of thrombotic events (TEs) were observed between groups. Notably, previous analyses of REVEAL identified TE history, disease duration, WBC count, and hematocrit level as risk factors of PV transformation to MF (Grunwald MR, ASH 2023).
Univariate logistic regression analyses identified higher age (odds ratio [OR], 1.020; 95% CI, 1.008, 1.033; P=0.0015), lower BMI (OR, 0.956; 95% CI, 0.928, 0.985; P=0.0032), WBC count >11.0×109/L (OR, 1.951; 95% CI, 1.422, 2.676; P<0.0001), and platelet count >400.0×109/L (OR, 2.317; 95% CI, 1.684, 3.189; P<0.0001) at enrollment as significant risk factors associated with progressive vs nonprogressive PV. A multivariate analysis also identified higher age (OR, 1.021; 95% CI, 1.007, 1.034; P=0.0032), lower BMI (OR, 0.968; 95% CI, 0.938, 0.998; P=0.0393), WBC count >11.0×109/L (OR, 1.534; 95% CI, 1.093, 2.153; P=0.0133), and platelet count >400.0×109/L (OR, 2.049; 95% CI, 1.450, 2.895; P<0.0001) at enrollment as factors associated with PV disease progression when considering the impact of other covariates. Disease duration and TE history were not identified as risk factors for PV progression in either analysis.
Significant persistent elevations in median WBC and median platelet counts were observed in patients with progressive PV compared with the control group up to month 18 after enrollment.
Conclusions: This analysis of REVEAL identified higher age, lower BMI, WBC count >11.0×109/L, and platelet count >400.0×109/L, but not TE history or disease duration, as risk factors at enrollment associated with early progressive PV. These results represent a method to identify patients with PV at risk of progression who could benefit from closer monitoring, earlier therapeutic intervention, and future risk-adapted treatment strategies using readily available clinical and laboratory data. The identification of a distinct progressive PV phenotype may also provide a clinically meaningful framework for evaluating molecular drivers of disease evolution and developing predictive models for progression.
DISCLOSURES
Michael R. Grunwald, MD: Medtronic - Stock (publicly traded); Takeda - Honoraria; Merck - Research Funding; Incyte - Research Funding; Ajax/Lilly - Research Funding; Disc Medicine - Research Funding; Deciphera - Research Funding; Ascentage - Research Funding; Johnson & Johnson - Research Funding; Takeda - Consultancy (Includes expert testimony); Geron - Consultancy (Includes expert testimony); Ascentage - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); Karyopharm - Consultancy (Includes expert testimony); Disc Medicine - Consultancy (Includes expert testimony); MJH - Consultancy (Includes expert testimony); Daiichi Sankyo - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Karius - Consultancy (Includes expert testimony); Cardinal Health - Consultancy (Includes expert testimony); Shorla - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); Autolus - Consultancy (Includes expert testimony); Aptitude Health - Consultancy (Includes expert testimony); Cogent Biosciences - Consultancy (Includes expert testimony); Premier - Consultancy (Includes expert testimony); Sanofi/Blueprint Medicines - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony)